4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

NCT06864988 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

480

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Interventions

BIOLOGICAL: 4D-150 IVT (3E10 vg/eye)
BIOLOGICAL: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Sponsor

4D Molecular Therapeutics